PI3K/Akt/mTOR通路在头颈部鳞状细胞癌中的靶向治疗研究进展

PI3K/Akt/mTOR signaling pathway on targeted therapies of head and neck squamous cell carcinoma

头颈部鳞状细胞癌(HNSCC)在全球最常见的恶性肿瘤中位居第六,晚期患者转移并复发率高,预后较差,为患者家庭和社会经济带来严重损失。靶向药物结合经典放化疗的个性化方案有望提高治疗功效并延长生存期。磷脂酰肌醇3?激酶/蛋白激酶B/哺乳动物雷帕霉素靶蛋白(PI3K/Akt/mTOR)在HNSCC中普遍存在过度激活,是控制肿瘤发生、发展及研发靶向药物的重要通路。本文就PI3K/Akt/mTOR通路应用于HNSCC靶向治疗的个体性差异发生的潜在机制,以及临床试验取得的进展与目前所面临的困境进行探讨,拟为HNSCC的临床靶向治疗提供参考思路,从而提高患者的生存质量。

Head and neck squamous cell carcinoma (HNSCC)is the sixth most common cause for cancer-related mortality worldwide.Personalized medicine of targeted drugs combined with classical radiotherapy and chemotherapy after surgery is expected to improve therapeutic efficacy and prolong survival rate of patients.It is known that increasing activation of PI3K/Akt/mTOR signaling pathway in HNSCC plays a central role to drive tumorigenesis and cancer metastasis.This article will explore the potential molecular mechanisms of individual differences in PI3K/Akt/mTOR signaling pathway applied in targeted therapy,the progress and current dilemmas of clinical trials,to provide a scheme for clinical treatment strategies to improve the life quality of the patients.